Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which are hormones that stimulate insulin release and decrease glucagon secretion. ## Primary Indications Type 2 diabetes mellitus, as an adjunct to diet and exercise. ## Adult Dosing 5 mg orally once daily. ## Pediatric Dosing The safety and efficacy of linagliptin in pediatric patients have not been established. ## Dose Adjustments No dose adjustment is required for patients with mild, moderate, or severe renal impairment. No dose adjustment is required for patients with any degree of hepatic impairment. ## Contraindications * Hypersensitivity to linagliptin or any excipient in the formulation. * History of serious hypersensitivity reactions to linagliptin. ## Adverse Effects Common adverse effects include nasopharyngitis, cough, diarrhea, and upper respiratory tract infection. Rare but serious adverse effects include pancreatitis, severe and disabling arthralgia, and hypersensitivity reactions. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** May decrease linagliptin exposure and efficacy. Consider alternative antihyperglycemic agents or increased monitoring. * **Sulfonylureas:** Increased risk of hypoglycemia. Lowering the sulfonylurea dose may be necessary. ## Monitoring * **Glycemic control:** HbA1c levels every 3-6 months. * **Pancreatitis:** Educate patients on symptoms of pancreatitis (persistent, severe abdominal pain, with or without vomiting) and advise them to discontinue immediately if pancreatitis is suspected. * **Hypersensitivity reactions:** Monitor for signs and symptoms. ## Clinical Pearls * Linagliptin is unique among DPP-4 inhibitors as it has a lower risk for accumulation in patients with renal or hepatic impairment, thus generally not requiring dose adjustments. * Consider the potential for hypoglycemia when used in combination with other antihyperglycemic agents, especially sulfonylureas or insulin. * Pancreatitis has been reported with linagliptin; patients should be counseled on the signs and symptoms. *** *This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information with the official product labeling or a reliable drug database.*